Incidence of Ototoxicity in Pediatric Patients with Transfusion-Dependent Thalassemia Who Are Less Well-Chelated by Mono- and Combined Therapy of Iron Chelating Agents

References

• Eleftheriou A. Introduction. In: Cappellini MD, Cohen A, Eleftheriou A, et al., Eds. Guidelines for the Clinical Management of Thalassaemia, 2nd ed. Nicosia, Cyprus: Thalassaemia International Federation. 2008:11–13
   Google Scholar
• Porter J. Iron overload. In: Cappellini MD, Cohen A, Eleftheriou A, et al., Eds. Guidelines for the Clinical Management of Thalassaemia, 2nd ed. Nicosia, Cyprus: Thalassaemia International Federation. 2008:33–63
   Google Scholar
• Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962;2(5319):1577–1580
   PubMed Web of Science ®Google Scholar
• Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977;297(8):418–423
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81–85
   PubMed Web of Science ®Google Scholar
• Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26–36
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193
   PubMed Web of Science ®Google Scholar
• Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferoxamine therapy. J Pediatr. 1990;117(2 Pt 1):326–330
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873
   PubMed Web of Science ®Google Scholar
• Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73(3):403–409
   PubMed Web of Science ®Google Scholar
• De Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassemia major. Acta Haematol. 1979;61(4):209–215
   PubMed Web of Science ®Google Scholar
• Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol. 1985;20(4):153–156
   PubMed Web of Science ®Google Scholar
• Karimi M, Asadi-Pooya AA, Khademi B, et al. Evaluation of the incidence of sensorineural hearing loss in β-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol. 2002;108(2):79–83
   PubMed Web of Science ®Google Scholar
• Chen SH, Liang DC, Lin HC, et al. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol. 2005;27(12):651–653
   PubMed Web of Science ®Google Scholar
• Chiodo AA, Alberti PW, Sher GD, et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol. 1997;26(2):116–122
   PubMedGoogle Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107(9):3455–3462
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88(4):251–260
   PubMed Web of Science ®Google Scholar
• Prasansuk S. Incidence/prevalence of sensorineural hearing impairment in Thailand and Southeast Asia. Audiology. 2000;39(4):207–211
   PubMedGoogle Scholar
• Masala W, Meloni F, Gallisai D, et al. Can deferoxamine be considered an ototoxic drug? Scand Audiol Suppl. 1988;30:237–238
   PubMedGoogle Scholar
• Albera R, Pia F, Morra B, et al. Hearing loss and desferrioxamine in homozygous β-thalassemia. Audiology. 1988;27(4):207–214
   PubMed Web of Science ®Google Scholar
• Wonke B, Hoffbrand AV, Aldouri M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child. 1989;64(1):77–82
   PubMed Web of Science ®Google Scholar
• Argiolu F, Diana G, Avignone A, et al. Hearing impairment during deferoxamine therapy for thalassemia major. J Pediatr. 1991;118(5):826–827
   PubMed Web of Science ®Google Scholar
• Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Pediatr Otorhinolaryngol. 1996;35(3):223–230
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: The Asian perspectives. Int J Hematol. 2009;90(4):435–445.25
   PubMed Web of Science ®Google Scholar
• Kusuwan T, Pangnukroh L, Leekamnerdthai W, et al. Analysis of treatment compliance and related health and social determining factors in Thai thalassemia patients under long-term deferrioxamine administration. Siriraj Nursing J. 2008;2(1):1–14
   Google Scholar
• De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child. 1988;63(3):250–255
   PubMed Web of Science ®Google Scholar
• Pall H, Blake DR, Winyard P, et al. Ocular toxicity of desferrioxamine — an example of copper promoted auto-oxidative damage? Br J Ophthalmol. 1989;73(1):42–47
   PubMed Web of Science ®Google Scholar
• Bentur Y, Koren G, Tesoro A, et al. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin Pharmacol Ther. 1990;47(4):478–482
   PubMed Web of Science ®Google Scholar